{"filings":[{"id":500076,"accession_number":"0001628280-26-035959","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2026-05-18T20:30:33+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medtronic neuroscience president Brett Wall to depart; Kweli Thompson named successor","event_type":"leadership","confidence":"high","bullets":["Brett Wall steps down as EVP & President, Neuroscience Portfolio; effective June 1, 2026.","Dr. Kweli Thompson moves from SVP & President, Cardiac Rhythm Management to succeed him.","Wall will remain an employee through September 1, 2026 to assist transition.","Severance consistent with Medtronic's executive severance practices per 2025 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94094,"accession_number":"0001628280-26-027272","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Medtronic discloses unauthorized access to corporate IT systems; no patient or product impact found","event_type":"cyber","confidence":"medium","bullets":["Unauthorized third party accessed data in certain Medtronic corporate IT systems; incident discovered April 24, 2026.","Company confirms no impact to products, patient safety, customer connections, manufacturing, or financial reporting systems.","Corporate IT networks are separate from product and manufacturing networks; hospital customer networks are separate and managed by customers.","Investigation ongoing; working to identify any personal information accessed and will provide notifications and support as needed.","Medtronic does not currently expect a material impact on its business or financial results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106212,"accession_number":"0001613103-26-000005","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Medtronic cuts FY2026 EPS guidance on MiniMed charges; FDA clears MiniMed Flex pump","event_type":"earnings","confidence":"high","bullets":["FDA cleared MiniMed Flex insulin pump several months earlier than expected; smartphone-controlled.","One-time $157M charge in Q4 FY2026 due to Blackstone royalty arrangement; $0.08 EPS impact.","MiniMed IPO (10% stake) closed Mar 9; dilutes Medtronic EPS by $0.04 in Q4 FY2026.","FY2026 non-GAAP EPS guidance revised to $5.50-$5.54 from $5.62-$5.66.","FY2027 high single-digit EPS growth guidance unchanged; Blackstone earns mid-to-high single digit royalty on first two years of net sales."],"consensus_eps_estimate":null,"consensus_eps_actual":2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":26557000000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106211,"accession_number":"0001628280-26-008300","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q3 FY2026: Revenue $9.02B (+6% organic), non-GAAP EPS $1.36 beats guidance; reiterates FY outlook","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.89; non-GAAP diluted EPS $1.36, three cents above Q3 guidance mid-point.","Cardiovascular portfolio revenue $3.46B (+10.6% organic); Cardiac Ablation Solutions up 80% on pulsed field ablation.","Diabetes revenue $796M (+8.3% organic); Neuroscience $2.56B (+2.5% organic); Medical Surgical $2.17B (+2.7% organic).","Reiterates FY26 organic revenue growth ~5.5% and non-GAAP EPS guidance $5.62-$5.66, including ~$185M tariff impact.","Secured FDA clearances for Hugo robotic-assisted surgery and Stealth AXiS; CE Mark for Sphere-360; completed CathWorks and Anteris acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":26557000000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122497,"accession_number":"0001628280-25-052771","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medtronic Q2 FY26: Revenue $9.0B (+5.5% organic), non-GAAP EPS $1.36 (+8%); raises FY26 guidance","event_type":"earnings","confidence":"high","bullets":["Q2 organic revenue growth 5.5% (beat guidance midpoint by 75 bps); GAAP EPS $1.07 (+8%), non-GAAP EPS $1.36 (+8%).","Cardiovascular revenue $3.44B (+9.3% organic); Cardiac Ablation Solutions up 71% on PFA portfolio.","Raises FY26 organic revenue growth guidance to ~5.5% (from ~5.0%); non-GAAP EPS guidance to $5.62-$5.66.","Received FDA approval for Altaviva device for urge UI; CMS NCD for Symplicity hypertension procedure.","Diabetes revenue $757M (+7.1% organic); Hugo robotic surgery study met safety and effectiveness endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":17539000000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122496,"accession_number":"0001628280-25-048375","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Medtronic EVP Enterprise Operations Gregory Smith to retire Dec 2, 2025","event_type":"leadership","confidence":"high","bullets":["Gregory L. Smith, EVP Enterprise Operations, notified retirement effective Dec 2, 2025 to join a private equity-held organization.","Retirement treatment of outstanding equity per proxy: accelerated unvested stock options, continued vesting of RSUs and PSUs.","No successor named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122495,"accession_number":"0001628280-25-045695","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Medtronic shareholders approve all proposals at 2025 AGM including director elections and bylaw amendments","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected; Craig Arnold received lowest support at 86.7% of votes cast.","Say-on-pay approved with 93.5% of votes cast in favor; ratification of PwC as auditor passed.","Shareholders approved amendment to Article 177 to capitalize non-distributable reserves and capital reduction to create distributable reserves.","Authority renewed to issue shares, opt out of pre-emption rights, and make overseas share purchases.","Advance notice provisions updated to strengthen shareholder proposal procedural requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139195,"accession_number":"0001193125-25-221819","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Medtronic issues €1.5B in senior notes; redeems €500M of 2025 notes","event_type":"debt","confidence":"high","bullets":["Issued €750M of 2.950% Senior Notes due 2030 and €750M of 4.200% Senior Notes due 2045.","Net proceeds of ~€1.49B; proceeds to repay Medtronic Luxco's 0.000% and 2.625% notes due 2025.","On Sept 29, redeemed all €500M of Medtronic Luxco's 2.625% Senior Notes due 2025 at par plus accrued interest.","Notes are guaranteed by Medtronic plc and Medtronic Luxco; listed on NYSE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139194,"accession_number":"0001193125-25-205061","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Medtronic prices €1.5B dual-tranche note offering; redeems €500M 2.625% notes due 2025","event_type":"debt","confidence":"high","bullets":["Issues €750M of 2.950% Senior Notes due 2030 and €750M of 4.200% Senior Notes due 2045.","Net proceeds intended to repay €500M of 2.625% Senior Notes due 2025 and €0% notes due 2025.","Redemption of 2.625% notes set for September 29, 2025, conditioned on closing of new notes.","Notes are fully and unconditionally guaranteed by Medtronic plc and Medtronic Global Holdings S.C.A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139193,"accession_number":"0001613103-25-000141","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Medtronic Q1 revenue $8.58B (+4.8% organic); raises FY26 EPS; adds 2 directors, forms new committees","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP EPS $0.81; non-GAAP EPS $1.26 (+2%), revenue $8.58B, organic growth 4.8%.","FY26 non-GAAP EPS guidance raised to $5.60-$5.66 from $5.50-$5.60; organic revenue growth ~5% reaffirmed.","Cardiac Ablation Solutions revenue +50% on pulsed field ablation strength; US +72%.","Board expanded to 13; John Groetelaars and William Jellison appointed as independent directors.","New Growth and Operations committees formed; Investor Day planned for mid-2026; engagement with Elliott Management."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":8578000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156748,"accession_number":"0001613103-25-000094","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medtronic appoints Dr. Joon Lee as independent director, effective June 18, 2025","event_type":"leadership","confidence":"high","bullets":["Board increased from 10 to 11 members; Dr. Lee appointed independent director.","Dr. Lee is CEO of Emory Healthcare, overseeing $7.7B revenue, 12 hospitals, 29,000+ employees.","He will serve on the Science & Technology and Compensation & Talent Committees.","Dr. Lee previously held executive roles at UPMC over 25 years, including EVP and President of Physician Services.","Appointment effective June 18, 2025; standard director compensation applies under existing policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156747,"accession_number":"0001613103-25-000078","cik":1613103,"company_name":"Medtronic plc","ticker":"MDT","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Medtronic Q4 EPS $1.62 non-GAAP (+11%); to spin off Diabetes; dividend raised to $0.71","event_type":"m_and_a","confidence":"high","bullets":["Q4 FY25 revenue $8.93B (+5.4% organic); non-GAAP EPS $1.62 (+11% as reported, +16% constant currency).","Plans to spin off Diabetes business into standalone public company within 18 months via IPO/split-off; accretive to margins and EPS.","Dividend raised to $0.71/quarter ($2.84 annual) — 48th consecutive annual increase; payable July 11, 2025.","Sean Salmon departs as EVP Cardiovascular; Skip Kiil promoted to EVP/President Cardiovascular Portfolio; Michael Carter to lead CST.","FY26 guidance: ~5% organic revenue growth; non-GAAP EPS $5.50-$5.60 reflecting tariff uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}